2157.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 04:08):

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China...

Stats
Today's Volume	4.21M
Average Volume	1.53M
Market Cap	8.09B
EPS	HKD0 ( 2023-08-25 )
Next earnings date	( HKD0 ) 2024-06-14
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-504.00
ATR14	HKD0.0280 (0.56%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.09 (neutral)

Signal:(50.601) Neutral

Lepu Biopharma Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lepu Biopharma Co., Ltd. Correlation - Currency/Commodity

0.57
( weak )

0.56
( weak )

0.00
( neutral )

0.65
( weak )

0.00
( neutral )

-0.82
( strong negative )

Lepu Biopharma Co., Ltd. Financials

Annual	2023
Revenue:	HKD225.35M
Gross Profit:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2023
Revenue:	HKD225.35M
Gross Profit:	HKD197.08M (87.45 %)
EPS:	HKD-0.0133

FY	2022
Revenue:	HKD15.57M
Gross Profit:	HKD13.57M (87.12 %)
EPS:	HKD-0.420

Financial Reports:

No articles found.

Lepu Biopharma Co., Ltd.

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.